{"id":11681,"date":"2018-10-04T08:59:45","date_gmt":"2018-10-04T12:59:45","guid":{"rendered":"https:\/\/medicarereport.org\/?p=11681"},"modified":"2018-10-04T08:59:45","modified_gmt":"2018-10-04T12:59:45","slug":"this-brand-new-advocacy-group-is-an-unapologetic-defender-of-high-drug-prices","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=11681","title":{"rendered":"This brand-new advocacy group is an unapologetic defender of high drug prices"},"content":{"rendered":"<p>(By Nicholas Florko for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">W<\/span><\/span>ASHINGTON \u2014 It\u2019s less than a week old, but a shadowy new pharma advocacy group is already launching diatribes against advocates for lower drug prices, blasting pharmacy middlemen and defending even sky-high list prices for prescription drugs. <a href=\"https:\/\/www.statnews.com\/2018\/10\/04\/advocacy-group-defends-high-drug-prices\/?utm_campaign=KHN%3A%20First%20Edition&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=66425572&amp;_hsenc=p2ANqtz-_TrD60HMJoi5ht7K-07mNftUcAt0dySFhukGeebpMakol5vmW8ZGaXLIo9OQpQ2qwr8FcY79Q4XNo3fgeqHHFEhAtR7w&amp;_hsmi=66425572\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Nicholas Florko for STAT) WASHINGTON \u2014 It\u2019s less than a week old, but a shadowy new pharma advocacy group<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-11681","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11681"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11681\/revisions"}],"predecessor-version":[{"id":11682,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11681\/revisions\/11682"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}